NASDAQ:INVA - Innoviva Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Innoviva Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.08 +0.01 (+0.07 %) (As of 02/18/2020 04:00 PM ET) Add Compare Today's Range$14.86Now: $15.08▼$15.1950-Day Range$13.79MA: $14.31▼$15.0852-Week Range$10.03Now: $15.08▼$16.29Volume315,205 shsAverage Volume602,663 shsMarket Capitalization$1.53 billionP/E Ratio10.55Dividend YieldN/ABeta1.42 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Innoviva, Inc engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorBasic Materials Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 CIK1080014 Webhttp://www.inva.com/ Phone650-238-9600Debt Debt-to-Equity Ratio0.40 Current Ratio1.76 Quick Ratio110.18Price-To-Earnings Trailing P/E Ratio10.55 Forward P/E Ratio11.25 P/E GrowthN/A Sales & Book Value Annual Sales$261.02 million Price / Sales5.85 Cash Flow$4.12 per share Price / Cash Flow3.66 Book Value$3.38 per share Price / Book4.46Profitability EPS (Most Recent Fiscal Year)$1.43 Net Income$157.29 million Net Margins60.35% Return on Equity58.66% Return on Assets23.89%Miscellaneous Employees6 Outstanding Shares101,279,000Market Cap$1.53 billion Next Earnings Date5/6/2020 (Estimated) OptionableOptionable Receive INVA News and Ratings via Email Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:INVA Rates by TradingView Innoviva (NASDAQ:INVA) Frequently Asked Questions What is Innoviva's stock symbol? Innoviva trades on the NASDAQ under the ticker symbol "INVA." How were Innoviva's earnings last quarter? Innoviva Inc (NASDAQ:INVA) released its quarterly earnings data on Wednesday, February, 5th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by $0.08. The biotechnology company had revenue of $75.97 million for the quarter. Innoviva had a net margin of 60.35% and a return on equity of 58.66%. View Innoviva's Earnings History. When is Innoviva's next earnings date? Innoviva is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Innoviva. Has Innoviva been receiving favorable news coverage? Media coverage about INVA stock has been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innoviva earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Innoviva. Who are some of Innoviva's key competitors? Some companies that are related to Innoviva include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Exelixis (EXEL), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), ZIOPHARM Oncology (ZIOP), Pfizer (PFE), Fate Therapeutics (FATE) and Bausch Health Companies (BHC). Who are Innoviva's key executives? Innoviva's management team includes the folowing people: Mr. Geoffrey Hulme, Interim Principal Exec. Officer (Age 52)Ms. Marianne Zhen CPA, Chief Accounting Officer (Age 50)Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VPDr. Kevin Kwok, Head of Talent Acquisition & Strategy Who are Innoviva's major shareholders? Innoviva's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (7.79%), LSV Asset Management (3.26%), State Street Corp (2.03%), First Eagle Investment Management LLC (1.64%), Man Group plc (1.31%) and Connor Clark & Lunn Investment Management Ltd. (0.59%). Company insiders that own Innoviva stock include Eric Desparbes, Geoffrey Hulme, George B Abercrombie, George Bickerstaff, Marianne Zhen and Theodore J Jr Witek. View Institutional Ownership Trends for Innoviva. Which major investors are selling Innoviva stock? INVA stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Baird Financial Group Inc., Man Group plc, Jane Street Group LLC, Chicago Equity Partners LLC, Connor Clark & Lunn Investment Management Ltd., Acadian Asset Management LLC and Barclays PLC. View Insider Buying and Selling for Innoviva. Which major investors are buying Innoviva stock? INVA stock was acquired by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Mackay Shields LLC, Great Lakes Advisors LLC, James Investment Research Inc., California Public Employees Retirement System and Great West Life Assurance Co. Can. Company insiders that have bought Innoviva stock in the last two years include Geoffrey Hulme and George Bickerstaff. View Insider Buying and Selling for Innoviva. How do I buy shares of Innoviva? Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Innoviva's stock price today? One share of INVA stock can currently be purchased for approximately $15.08. How big of a company is Innoviva? Innoviva has a market capitalization of $1.53 billion and generates $261.02 million in revenue each year. The biotechnology company earns $157.29 million in net income (profit) each year or $1.43 on an earnings per share basis. Innoviva employs 6 workers across the globe.View Additional Information About Innoviva. What is Innoviva's official website? The official website for Innoviva is http://www.inva.com/. How can I contact Innoviva? Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected] MarketBeat Community Rating for Innoviva (NASDAQ INVA)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 279 (Vote Outperform)Underperform Votes: 364 (Vote Underperform)Total Votes: 643MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2020 by MarketBeat.com StaffFeatured Article: What is a back-end load?
